DefinitionThis section has been translated automatically.
Spectrum of actionThis section has been translated automatically.
Inhibition of squalene epoxidase, accumulation of fungicidally active squalene. Excretion: 71% renal, 22% fecal.
In the meantime, acquired terbinafine resistance has occurred in several countries. It results from a missense mutation in the SQLE gene, the target of terbinafine. Cases of terbinafine-resistant T. indotineae with clinical failure have been reported mainly in Germany and Iran (Tamimi P et al. 2024).
You might also be interested in
IndicationThis section has been translated automatically.
Infections with dermatophytes ( tinea capitis, tinea corporis, onychomycosis). Also effective in sporotrichosis ( off-label use). The efficacy in sporotrichosis was demonstrated in 2 studies. Also effective in mixed infections with Candida species (mycelial form) and Scopularopsis.
Dosage and method of useThis section has been translated automatically.
Standard concentrationThis section has been translated automatically.
Undesirable effectsThis section has been translated automatically.
Allergic reactions, rarely Quincke's edema and drug-induced Lyell syndrome, AGEP, disorders of the sense of taste, BB changes (neutropenia, thrombocytopenia), gastrointestinal disorders, arthralgias, myalgias, rarely liver cell damage up to fatal liver cell necrosis.
Deterioration of psoriasis.
Notice! Due to the side effects, systemic use in Sweden has been limited to therapy-resistant onychomycoses!
InteractionsThis section has been translated automatically.
ContraindicationThis section has been translated automatically.
PreparationsThis section has been translated automatically.
Topical: e.g. Lamisil Pedisan cream, DermGel and spray.
Systemic: e.g. Lamisil, Terbinafine
Note(s)This section has been translated automatically.
In Switzerland and Austria Terbinafine is approved for oral application in children, in Germany however not yet ( off-label use). A careful documentation and education of parents about the off-label use and the effect of Terbinafine in studies should be carried out. The dosage recommendation is: Children with 10-20 kg bw: 62.5 mg/day; 21-40 kg bw: 125 mg/day; > 40 kg bw: 250 mg/day. 2 weeks of therapy are normally sufficient.
In a randomized double-blind study it could be shown that a therapy with Terbinafine cream 1% over 7 days (once/day) is sufficient to cure a Tinea pedis interdigitalis.
LiteratureThis section has been translated automatically.
- Seebacher C et al (2006) Tinea capitis. J Dtsch Dermatol Ges 4: 1085-1091
- Seebacher C et al (2007) Tinea of the free skin. J Dtsch Dermatol Ges 11: 921-926
Tamimi P et al. (2024) Terbinafine-resistant T. indotineae due to F397L/L393S or F397L/L393F mutation among corticoid-related tinea incognita patients. J Dtsch Dermatol Ges 22:922-934.
Wilmer A et al. (1998) Systemic terbinafine treatment of dermatophytoses in children. Mycoses 41: 54-57